Home › Compound Library › Guanfacine Extended Release (Intuniv)

Guanfacine Extended Release (Intuniv)

Antihypertensive / Alpha-2 Agonistprescriptionoral · inferred

Once-daily extended-release guanfacine matrix tablet for ADHD. Swallow whole; do not crush, chew, or break. Not substitutable for immediate-release guanfacine on a milligram-per-milligram basis.

Projected serum levels — 1 mg, once daily

Guanfacine Extended Release (Intuniv)
Guanfacine Extended Release (Intuniv) modeled serum levels, 1 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 2 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 2
Guanfacine Extended Release (Intuniv) modeled serum levels with a loading dose of 1.6 mg, then 1 mg once daily The first dose is larger so levels approach steady state faster. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 1 mg once daily (oral).

Loading schedule: 1.6 mg on day 1, then 1 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~2 days: peak ≈ 0.61 mg, trough ≈ 0.29 mg body load. Population-based estimate over 15 days for a 1 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antihypertensive / Alpha-2 Agonist
Route modeled
Oral
Model confidence
inferred
Half-life
17 h
Common dose
1 mg
Suggested maximum
7 mg/day
Reference dose range
1–7 mg (single dose)
Suggested cadence
once daily
Validated against
1 mg oral — Cmax 0.001 mg/L at 5 h